CN116785424A - 一种mRNA多价流感疫苗及其制备方法 - Google Patents
一种mRNA多价流感疫苗及其制备方法 Download PDFInfo
- Publication number
- CN116785424A CN116785424A CN202311034211.2A CN202311034211A CN116785424A CN 116785424 A CN116785424 A CN 116785424A CN 202311034211 A CN202311034211 A CN 202311034211A CN 116785424 A CN116785424 A CN 116785424A
- Authority
- CN
- China
- Prior art keywords
- mrna
- recombinant protein
- mice
- nucleotide sequence
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004999 messenger RNA Proteins 0.000 title claims abstract description 99
- 229960003971 influenza vaccine Drugs 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 70
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 70
- 229960005486 vaccine Drugs 0.000 claims abstract description 12
- 239000002773 nucleotide Substances 0.000 claims description 45
- 125000003729 nucleotide group Chemical group 0.000 claims description 45
- 239000002105 nanoparticle Substances 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 8
- 238000013518 transcription Methods 0.000 claims description 8
- 230000035897 transcription Effects 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 238000001976 enzyme digestion Methods 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 241000699670 Mus sp. Species 0.000 abstract description 81
- 230000004083 survival effect Effects 0.000 abstract description 35
- 239000000427 antigen Substances 0.000 abstract description 23
- 102000036639 antigens Human genes 0.000 abstract description 23
- 108091007433 antigens Proteins 0.000 abstract description 23
- 241000700605 Viruses Species 0.000 abstract description 18
- 238000002474 experimental method Methods 0.000 abstract description 9
- 230000002685 pulmonary effect Effects 0.000 abstract description 5
- 230000005847 immunogenicity Effects 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000002829 reductive effect Effects 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 description 31
- 241000712461 unidentified influenza virus Species 0.000 description 25
- 238000005457 optimization Methods 0.000 description 19
- 239000013598 vector Substances 0.000 description 16
- 230000037396 body weight Effects 0.000 description 15
- 206010022000 influenza Diseases 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 208000037797 influenza A Diseases 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 102220527160 Immunoglobulin heavy joining 1_H11N_mutation Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241001500351 Influenzavirus A Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000037798 influenza B Diseases 0.000 description 3
- 108700021021 mRNA Vaccine Proteins 0.000 description 3
- 229940126582 mRNA vaccine Drugs 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 2
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- 241001500350 Influenzavirus B Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000002296 dynamic light scattering Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000000185 hemagglutinin Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- NLJUOWMZPAVXHU-UHFFFAOYSA-N prop-2-enamide;urea Chemical compound NC(N)=O.NC(=O)C=C NLJUOWMZPAVXHU-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101100460704 Aspergillus sp. (strain MF297-2) notI gene Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241000223924 Eimeria Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 description 1
- 101000986379 Homo sapiens High mobility group protein HMGI-C Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 101710180643 Leishmanolysin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- 108091036407 Polyadenylation Proteins 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000006450 immune cell response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960000172 trivalent influenza vaccine Drugs 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明提供一种mRNA多价流感疫苗及其制备方法,所述疫苗包括重组蛋白H1N1的mRNA、重组蛋白H3N2的mRNA、重组蛋白H5N1的mRNA、重组蛋白H6N1的mRNA、重组蛋白H7N9的mRNA、重组蛋白H9N2的mRNA、重组蛋白H11N2的mRNA、重组蛋白B‑Victoria的mRNA、重组蛋白B‑Yamagata的mRNA;所述疫苗中各mRNA的质量浓度均为100μg/mL;本发明对抗原序列进行了优化,制备的mRNA多价流感疫苗能够刺激机体产生较强的免疫原性,和序列优化前制备的mRNA多价流感疫苗相比,抗体滴度明显提高,攻毒实验后小鼠的存活率明显提高,小鼠肺脏病毒滴度明显降低。
Description
技术领域
本发明涉及一种mRNA多价流感疫苗及其制备方法,属于医用配制品技术领域。
背景技术
流感是由正粘病毒科的RNA病毒引起的传染病,可以感染鸟类和哺乳动物。流感通常通过咳嗽或打喷嚏产生的气溶胶以及直接接触含有病毒的体液或被污染的表面传播。甲型流感病毒和B型流感病毒容易引起季节性流行。
目前的流感病毒疫苗主要诱导针对血凝素(病毒的主要表面糖蛋白)的免疫显性和可变头部结构域的免疫应答,但对抗原漂移或转移病毒的保护能力有限,需要开发有效的、具有广泛保护作用的疫苗。研究发现血凝素茎结构域含有中和的B细胞表位,这些表位在甲型流感病毒亚型之间都是保守的,因此它可以引发免疫细胞应答来防御外来流感攻击。
近年来,随着免疫学技术的不断深入和基因工程技术的迅速发展,DNA重组疫苗、合成肽疫苗、mRNA疫苗等新型疫苗不断涌现。其中mRNA疫苗作为一种核酸疫苗,能够表达任何蛋白质,可以从基因水平上治疗几乎所有基于蛋白质的疾病。相较于其他传统疫苗和DNA疫苗技术,mRNA疫苗的合成不仅生产工艺简单,且价格低廉。同时这种人为设计的核酸并不会诱发人体的免疫反应,不进入细胞核,无整合到基因组的风险,相对更安全。
目前市面上的流感疫苗主要为三价流感疫苗或四价流感疫苗,为减毒活疫苗或灭活疫苗,通过在胚胎鸡蛋中繁殖病毒生产,其生产时间长,由于流行病毒的抗原快速进化,其疗效有限;抗原可变性介导病毒逃离宿主免疫反应,需要每年更新疫苗。
现有技术中还未有mRNA的流感疫苗被报道。
发明内容
针对现有技术存在的不足,本发明提供一种mRNA多价流感疫苗及其制备方法,实现以下发明目的:能够广泛地对多种流感毒株产生交叉反应,可以治疗和预防流感病毒,且免疫和治疗效果好。
为解决上述技术问题,本发明采取以下技术方案:
一种mRNA多价流感疫苗,所述疫苗包括重组蛋白H1N1的mRNA、重组蛋白H3N2的mRNA、重组蛋白H5N1的mRNA、重组蛋白H6N1的mRNA、重组蛋白H7N9的mRNA、重组蛋白H9N2的mRNA、重组蛋白H11N2的mRNA、重组蛋白B-Victoria的mRNA、重组蛋白B-Yamagata的mRNA;所述疫苗中各mRNA的质量浓度均为100μg/mL;所述mRNA由脂质纳米粒包封;所述重组蛋白H1N1的核苷酸序列如序列表SEQ ID NO.3所示;所述重组蛋白H3N2的核苷酸序列如序列表中SEQ ID NO.4所示;所述重组蛋白H5N1的核苷酸序列如序列表SEQ ID NO.5所示;所述重组蛋白H6N1的核苷酸序列如序列表SEQ ID NO.6所示;所述重组蛋白H7N9的核苷酸序列如序列表SEQ ID NO.7所示;所述重组蛋白H9N2的核苷酸序列如序列表SEQ ID NO.8所示;所述重组蛋白H11N2的核苷酸序列如序列表SEQ ID NO.9所示;所述重组蛋白B-Victoria的核苷酸序列如序列表SEQ ID NO.10所示;所述重组蛋白B-Yamagata的核苷酸序列如序列表SEQ ID NO.11所示。
所述mRNA多价流感疫苗的制备方法,将各重组蛋白的核苷酸序列分别连接到载体上,得到重组载体,然后将重组载体进行线性化酶切,回收目的DNA片段,经体外转录得到各重组蛋白的mRNA,经脂质纳米粒包装后,混合得到mRNA多价流感疫苗。
与现有技术相比,本发明取得以下有益效果:
(1)本发明对抗原序列进行了优化,制备的mRNA多价流感疫苗能够刺激机体产生较强的免疫原性,和序列优化前制备的mRNA多价流感疫苗相比,抗体滴度明显提高,攻毒实验后小鼠的存活率明显提高,小鼠肺脏病毒滴度明显降低。
(2)本发明制备的mRNA多价流感疫苗对小鼠具有显著的交叉保护作用,可同时抵抗多种流感毒株的侵染。
附图说明
图1为本发明重组蛋白结构的设计图;
图2为实施例3体外转录得到的mRNA的电泳图;
图3为不同抗原包板检测mRNA多价流感疫苗免疫小鼠血清抗体效价的柱状图;
图4为感染A/Beijing/262/1995(H1N1)流感病毒后各组小鼠生存曲线和体重变化图;
其中图4A为感染A/Beijing/262/1995(H1N1)流感病毒后各组小鼠生存曲线图;图4B为感染A/Beijing/262/1995(H1N1)流感病毒后各组小鼠体重变化图;
图5为感染A/Perth/16/2009(H3N2)流感病毒后各组小鼠生存曲线和体重变化图;
其中图5A为感染A/Perth/16/2009(H3N2)流感病毒后各组小鼠生存曲线图;图5B为感染A/Perth/16/2009(H3N2)流感病毒后各组小鼠体重变化图;
图6为感染A/Anhui/1/2005(H5N1)流感病毒后各组小鼠生存曲线和体重变化图;
其中图6 A为感染A/Anhui/1/2005(H5N1)流感病毒后各组小鼠生存曲线图;图6B为感染A/Anhui/1/2005(H5N1)流感病毒后各组小鼠体重变化图;
图7为感染A/quail/Hong Kong/1721-30/99(H6N1)流感病毒后各组小鼠生存曲线和体重变化图;
其中图7 A为感染A/quail/Hong Kong/1721-30/99(H6N1)流感病毒后各组小鼠生存曲线图;图7B为感染A/quail/Hong Kong/1721-30/99(H6N1)流感病毒后各组小鼠体重变化图;
图8为感染A/Anhui/01/2013(H7N9)流感病毒后各组小鼠生存曲线和体重变化图;
其中图8 A为感染A/Anhui/01/2013(H7N9)流感病毒后各组小鼠生存曲线图;图8B为感染A/Anhui/01/2013(H7N9)流感病毒后各组小鼠体重变化图;
图9为感染A/Hong Kong/1073/1999(H9N2)流感病毒后各组小鼠生存曲线和体重变化图;
图9 A为感染A/Hong Kong/1073/1999(H9N2)流感病毒后各组小鼠生存曲线图;图9B为感染A/Hong Kong/1073/1999(H9N2)流感病毒后各组小鼠体重变化图;
图10为感染A/duck/Yangzhou/906/2002(H11N2)流感病毒后各组小鼠生存曲线和体重变化图;
其中图10 A为感染A/duck/Yangzhou/906/2002(H11N2)流感病毒后各组小鼠生存曲线图;图10B为感染A/duck/Yangzhou/906/2002(H11N2)流感病毒后各组小鼠体重变化图;
图11为感染B/Florida/78/2015(B/Victoria)流感病毒后各组小鼠生存曲线和体重变化图;
其中图11 A为感染B/Florida/78/2015(B/Victoria)流感病毒后各组小鼠生存曲线图;图11B为感染B/Florida/78/2015(B/Victoria)流感病毒后各组小鼠体重变化图;
图12为感染B/Wisconsin/1/2010 BX-41A(B/Yamagata)流感病毒后各组小鼠生存曲线和体重变化图;
其中图12 A为感染B/Wisconsin/1/2010 BX-41A(B/Yamagata)流感病毒后各组小鼠生存曲线图;图12B为感染B/Wisconsin/1/2010 BX-41A(B/Yamagata)流感病毒后各组小鼠体重变化图。
具体实施方式
实施例1 重组蛋白载体的构建
重组蛋白结构的设计图如图1所示。
重组蛋白从N端到C端依次包括DC结合区(其核苷酸序列为SEQ ID NO.1)、抗原、Foldon折叠蛋白(其核苷酸序列为SEQ ID NO.2);
所述抗原为H1N1、H3N2、H5N1、H6N1、H7N9、H9N2、H11N2、B-Victoria或B-Yamagata;
不同的抗原分别重组得到对应的重组蛋白。
各重组蛋白的核苷酸序列如下:
(1)重组蛋白H1N1的核苷酸序列(SEQ ID NO.3)
(2)重组蛋白H3N2的核苷酸序列(SEQ ID NO.4)
(3)重组蛋白H5N1的核苷酸序列(SEQ ID NO.5)
(4)重组蛋白H6N1的核苷酸序列(SEQ ID NO.6)
(5)重组蛋白H7N9的核苷酸序列(SEQ ID NO.7)
(6)重组蛋白H9N2的核苷酸序列(SEQ ID NO.8)
(7)重组蛋白H11N2的核苷酸序列(SEQ ID NO.9)
(8)重组蛋白B-Victoria的核苷酸序列(SEQ ID NO.10)
(9)重组蛋白B-Yamagata的核苷酸序列(SEQ ID NO.11);
按照上述各种重组蛋白的核苷酸序列,委托山东弘诺生物科技有限公司合成,将其分别连接到PVAX1载体上,获得的重组载体命名为PVAX1-H1、PVAX1-H3、PVAX1-H5、PVAX1-H6、PVAX1-H7、PVAX1-H9、PVAX1-H11、PVAX1-B-Victoria、PVAX1-B-Yamagata。按照常规实验方法对这些载体进行转化、摇菌并提取质粒,各种质粒的浓度为1.0μg/μL,得到9种PVAX1重组载体。
本申请对H7N9、H9N2的抗原序列进行了优化,优化情况如下:
H7N9抗原序列:优化前H7N9抗原的氨基酸序列是选取A/chicken/Guangxi/97/2017(H7N9)(QAU56257.1)中19-55位置的氨基酸和296-530位置的氨基酸,两者之间用GSA连接;优化后H7N9抗原的氨基酸序列是在优化前H7N9抗原的氨基酸序列基础上去掉81-95位氨基酸,用GSAGSA连接前后的氨基酸序列。
将优化前H7N9抗原的氨基酸序列翻译得到核苷酸序列,N端连接DC结合区的核苷酸序列(SEQ ID NO.1),C端连接Foldon折叠蛋白的核苷酸序列(SEQ ID NO.2),得到优化前重组蛋白H7N9的核苷酸序列(SEQ ID NO.12)。
H9N2抗原序列:优化前H9N2抗原的氨基酸序列是选取A/Quail/Shanghai/8/96(H9N2)(AAQ04863.1)中15-53位置的氨基酸和292-521位置的氨基酸,两者之间用GSA连接;优化后H9N2抗原的氨基酸序列是在优化前H9N2抗原的氨基酸序列基础上去掉81-95位氨基酸,用GSAGSA连接前后的氨基酸序列。
将优化前H9N2抗原的氨基酸序列翻译得到核苷酸序列,N端连接DC结合区的核苷酸序列(SEQ ID NO.1),C端连接Foldon折叠蛋白的核苷酸序列(SEQ ID NO.2),得到优化前重组蛋白H9N2的核苷酸序列(SEQ ID NO.13)。
按照优化前重组蛋白H7N9、优化前重组蛋白H9N2的核苷酸序列,委托山东弘诺生物科技有限公司合成,将其分别连接到PVAX1载体上,获得的重组载体分别命名为PVAX1-H7-优化前、PVAX1-H9-优化前。按照常规实验方法对这些载体进行转化、摇菌并提取质粒,各质粒的浓度为1.0μg/μL,得到2种PVAX1重组载体。
实施例2 重组载体线性化酶切及回收
针对重组载体,选用Not I限制性酶来单酶切重组PVAX1载体,优化后酶切体系(共50μL)如下:
10×Buffer:5μL;NotI酶:3μL;PVAX1重组载体:2μL (1μg/μL);水:40μL。
11种重组载体分别进行单酶切反应:在37℃水浴锅中酶切1h,迅速转入65℃水浴锅中5min,终止酶切反应。
在1%琼脂糖凝胶电泳鉴定,所得片段大小符合预期,切下目的片段,利用琼脂糖凝胶DNA回收试剂盒对目的片段进行回收,用分光光度计测量回收的DNA浓度,将DNA浓度调为1μg/μL,保存于-20℃备用。
实施例3 体外转录mRNA(IVT mRNA)
将实施例2得到的DNA进行体外转录mRNA,具体方法为根据CN113577258A专利中实施例3记载的体外转录mRNA的方法,使用加帽mMESSAGE mMACHINE T7 kit (Ambion公司),体外转录合成5′加帽的mRNA,同时对mRNA进行3′端加Poly(A)尾结构,获得5′加帽和3′加尾结构的mRNA,调整mRNA的浓度为2μg/μL。
将mRNA置于70℃水浴锅中10min,冰上放置3min,在尿素丙烯酰胺胶中进行电泳,100v恒压电泳30min,凝胶成像仪拍照,验证mRNA的大小和完整性。
结果如图2所示,对11种线性化的PVAX1重组载体体外转录成的mRNA,在尿素丙烯酰胺胶中进行电泳,所得mRNA与设计的核苷酸大小相符。
实施例4 包装mRNA的LNP(脂质纳米粒)的制备及其表征分析
根据CN113577258A专利中实施例4记载的LNP的制备方法制备相应的mRNA的LNP颗粒,制备的mRNA的LNP颗粒分别命名为LNP-H1、LNP-H3、LNP-H5、LNP-H6、LNP-H7、LNP-H9、LNP-H11、LNP-B-Victoria、LNP-B-Yamagata、LNP-H7-优化前、LNP-H9-优化前、LNP-空白;部分颗粒进行表征,剩余颗粒进行透析、超离心过滤浓缩,去除未包封的mRNA。
所述透析、超离心过滤浓缩的方法为:将mRNA的LNP颗粒在PBS溶液( PH7 .4)中透析24 h,透析完得到含有LNP的溶液,使用Amicon超离心过滤器浓缩至体积为1mL,过0.22um滤膜2次,保存于-20℃备用。
对制备的mRNA的LNP颗粒进行表征分析,包括纳米颗粒的大小、分散指数、包封率测定。
采用动态光散射法(DLS法)对制备纳米颗粒的大小和分散指数(PDI)情况进行分析,采用Quant-iT™ RiboGreen® RNA Reagent and Kit(购自Invitorgen)测量纳米粒子的包封率。
结果如表1所示,所得mRNA的LNP颗粒的包封率高达85%以上,mRNA基本全部被包裹。
表1 纳米颗粒的表征
实施例5 mRNA多价流感疫苗的制备及其免疫效果
一、mRNA多价流感疫苗的制备
将LNP-H1、LNP-H3、LNP-H5、LNP-H6、LNP-H7、LNP-H9、LNP-H11、LNP-B-Victoria、LNP-B-Yamagata经透析、超离心过滤浓缩,去除未包封的mRNA后,得到的9种mRNA的LNP颗粒均用PBS溶液(购自索莱宝,货号:P1020)调整mRNA浓度到1mg/mL,按照等体积比例进行混合,密封好样品,再加入同样体积的PBS溶液(购自索莱宝,货号:P1020),置于4℃缓慢摇晃16h后,使各种优化后抗原终浓度均为100μg/mL,得到mRNA多价流感疫苗。
按照同样的方法和浓度制备优化前多价流感疫苗,具体方法为将LNP-H7-优化前替换LNP-H7,制备成H7-优化前mRNA多价流感疫苗,将LNP-H9-优化前替换LNP-H9制备成H9-优化前mRNA多价流感疫苗。
二、流感疫苗的免疫原性
(1)免疫方式及实验分组
用制备的mRNA多价流感疫苗为抗原,采用SPF级BABL/c小鼠为动物模型,注射免疫剂量50μg/0.5mL/只/次,初次免疫后14d加强一次免疫,28d采血,利用酶联免疫吸附法检测免疫小鼠血清ELISA抗体效价。实验分组如表2。
表2 免疫小鼠实验分组
(2)检测
采用酶联免疫吸附法(ELISA法)进行检测,分别使用重组蛋白H1N1、重组蛋白H3N2、重组蛋白H5N1、重组蛋白H6N1、重组蛋白H7N9、重组蛋白H9N2、重组蛋白H11N2、重组蛋白B-Victoria、重组蛋白B-Yamagata包板检测mRNA多价流感疫苗免疫小鼠血清ELISA抗体效价(IgG)。
(3)结果分析
结果如图3和表3所示,使用本发明所制备的mRNA多价流感疫苗以100μg/只的剂量经腹腔免疫接种BALB/c小鼠后产生了高滴度的IgG抗体。说明本发明所制备的mRNA多价流感疫苗能够刺激机体产生较强的免疫原性。免疫原优化后的抗体滴度显著高于优化前的抗体滴度。优化后的免疫原在不同的多价流感疫苗之间均能产生相似的抗体滴度,表明多血清型抗原制备成联合疫苗后,各血清型之间无免疫抑制效果。
表3 mRNA多价流感疫苗免疫小鼠的抗体效价
实施例6 流感毒株感染保护实验
1、本实施例中使用的病毒株
毒株1:H1N1人流感病毒A/Beijing/262/1995
毒株2:H3N2人流感病毒A/Perth/16/2009
毒株3:H5N1人流感病毒A/Anhui/1/2005
毒株4:H6N1禽流感病毒A/quail/Hong Kong/1721-30/99
毒株5:H7N9禽流感病毒A/Anhui/01/2013
毒株6:H9N2禽流感病毒A/Hong Kong/1073/1999
毒株7:H11N2禽流感病毒A/duck/Yangzhou/906/2002
毒株8:B/Victoria人流感病毒 B/Florida/78/2015
毒株9:B/Yamagata人流感病毒B/Wisconsin/1/2010 BX-41A
毒株1-3购自武汉艾美捷科技有限公司,毒株4-7由中国疾病控制中心病毒病研究所提供,毒株8-9购自ATCC。
2、实验方法及分组
根据免疫样品和攻击毒株的不同将小鼠随机分为20组,12只/组,雌雄各半。每组选取2只小鼠(一雌一雄)用于肺脏病毒滴度检测,其余10只用于生存率实验;免疫样品分别为mRNA多价流感疫苗和LNP-空白组,攻击毒株为上述9种毒株,实验分组见表4。注射免疫剂量50μg/0.5mL/只/次,初次免疫后14d加强一次免疫,21d小鼠经乙醚麻醉,待小鼠进入麻醉状态,从鼻腔滴注107PFU的流感病毒,每天监测小鼠存活状况,监测期为14天。
取攻毒4天后的小鼠肺脏进行病毒滴度检测:取攻毒4天的小鼠,雌雄各一只,拉颈处死,无菌状态下取出肺脏,称重后与研磨钵中研磨,按照1g肺脏组织:10mL PBS的比例制备肺组织匀浆,取出置于1.5mL Ep管中,2000g离心10分钟,取上清,测PFU。
表4 攻毒实验分组表
3、结果分析
(1)攻毒后14天内小鼠存活情况
图4为A/Beijing/262/1995(H1N1)攻毒后各组小鼠生存曲线图和体重变化图。由图4可知,攻毒后,mRNA多价流感疫苗组小鼠体重基本不变,且100%存活;LNP-空白组小鼠体重持续下降,于攻毒后第12天全部死亡。
图5为A/Perth/16/2009(H3N2)攻毒后各组小鼠生存曲线图和体重变化图。由图5可知,攻毒后,mRNA多价流感疫苗组小鼠体重先降低后升高,且90%存活;LNP-空白组小鼠体重持续下降,于攻毒后第10天全部死亡。
图6为A/Anhui/1/2005(H5N1)攻毒后各组小鼠生存曲线图和体重变化图。由图6可知,攻毒后,mRNA多价流感疫苗组小鼠体重基本不变,且100%存活;LNP-空白组小鼠体重持续下降,于攻毒后第9天全部死亡。
图7为A/quail/Hong Kong/1721-30/99(H6N1)攻毒后各组小鼠生存曲线图和体重变化图。由图7可知,攻毒后,mRNA多价流感疫苗组小鼠体重基本不变,且100%存活;LNP-空白组小鼠于攻毒后第7天小鼠全部死亡。
图8为A/Anhui/01/2013(H7N9)攻毒后各组小鼠生存曲线图和体重变化图。由图8可知,攻毒后,mRNA多价流感疫苗组小鼠体重基本不变,且100%存活;H7-优化前mRNA多价流感疫苗组小鼠体重基本不变,存活率为60%;LNP-空白组小鼠体重持续下降,于攻毒后第13天全部死亡。
图9为A/Hong Kong/1073/1999(H9N2)攻毒后各组小鼠生存曲线图和体重变化图。由图9可知,攻毒后,mRNA多价流感疫苗组小鼠体重基本不变,且100%存活;H9-优化前mRNA多价流感疫苗组小鼠体重基本不变,存活率为70%;LNP-空白组小鼠体重持续下降,于攻毒后第9天全部死亡。
图10为A/duck/Yangzhou/906/2002(H11N2)攻毒后各组小鼠生存曲线图和体重变化图。由图10可知,攻毒后,mRNA多价流感疫苗组小鼠体重先降低后升高,且90%存活;LNP-空白组小鼠体重持续下降,于攻毒后第10天全部死亡。
图11为B/Florida/78/2015(B/Victoria)攻毒后各组小鼠生存曲线图和体重变化图。由图11可知,攻毒后,mRNA多价流感疫苗组小鼠体重基本不变,且100%存活;LNP-空白组小鼠体重持续下降,于攻毒后第11天全部死亡。
图12为B/Wisconsin/1/2010 BX-41A(B/Yamagata)攻毒后各组小鼠生存曲线图和体重变化图。由图12可知,攻毒后,mRNA多价流感疫苗组小鼠体重下降,后期小鼠体重上升,部分小鼠无法抵抗病毒而死亡,观察期结束,小鼠存活率为70%;LNP-空白组小鼠体重持续下降,于攻毒后第9天全部死亡。
(2)攻毒后4天小鼠肺脏病毒滴度检测
攻毒4天后小鼠肺脏病毒滴度检测结果如表5所示,mRNA多价流感疫苗免疫后的小鼠体内的病毒滴度明显低于对照组,说明本发明制备的mRNA多价流感疫苗对小鼠具有显著的交叉保护作用,可同时抵抗多种流感毒株的侵染。
表5攻毒4天后小鼠肺脏病毒滴度
。/>
Claims (2)
1.一种mRNA多价流感疫苗,其特征在于:所述疫苗包括重组蛋白H1N1的mRNA、重组蛋白H3N2的mRNA、重组蛋白H5N1的mRNA、重组蛋白H6N1的mRNA、重组蛋白H7N9的mRNA、重组蛋白H9N2的mRNA、重组蛋白H11N2的mRNA、重组蛋白B-Victoria的mRNA、重组蛋白B-Yamagata的mRNA;所述疫苗中各mRNA的质量浓度均为100μg/mL;所述mRNA由脂质纳米粒包封;所述重组蛋白H1N1的核苷酸序列如序列表SEQ ID NO.3所示;所述
重组蛋白H3N2的核苷酸序列如序列表中SEQ ID NO.4所示;所述重组蛋白H5N1的核苷酸序列如序列表SEQ ID NO.5所示;所述重组蛋白H6N1的核苷酸序列如序列表SEQ ID NO.6所示;所述重组蛋白H7N9的核苷酸序列如序列表SEQ ID NO.7所示;所述重组蛋白H9N2的核苷酸序列如序列表SEQ ID NO.8所示;所述重组蛋白H11N2的核苷酸序列如序列表SEQ IDNO.9所示;所述重组蛋白B-Victoria的核苷酸序列如序列表SEQ ID NO.10所示;所述重组蛋白B-Yamagata的核苷酸序列如序列表SEQ ID NO.11所示。
2.权利要求1所述mRNA多价流感疫苗的制备方法,其特征在于:将各重组蛋白的核苷酸序列分别连接到载体上,得到重组载体,然后将重组载体进行线性化酶切,回收目的DNA片段,经体外转录得到各重组蛋白的mRNA,经脂质纳米粒包装后,混合得到mRNA多价流感疫苗。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311034211.2A CN116785424B (zh) | 2023-08-17 | 2023-08-17 | 一种mRNA多价流感疫苗及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311034211.2A CN116785424B (zh) | 2023-08-17 | 2023-08-17 | 一种mRNA多价流感疫苗及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116785424A true CN116785424A (zh) | 2023-09-22 |
CN116785424B CN116785424B (zh) | 2023-11-03 |
Family
ID=88049962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311034211.2A Active CN116785424B (zh) | 2023-08-17 | 2023-08-17 | 一种mRNA多价流感疫苗及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116785424B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200163878A1 (en) * | 2016-10-26 | 2020-05-28 | Curevac Ag | Lipid nanoparticle mrna vaccines |
US20210162037A1 (en) * | 2016-05-04 | 2021-06-03 | Curevac Ag | Influenza mrna vaccines |
CN113372416A (zh) * | 2021-06-29 | 2021-09-10 | 山西高等创新研究院 | 流感病毒ha颈部区的突变体、重组蛋白及其应用 |
US20220370599A1 (en) * | 2021-04-30 | 2022-11-24 | Greenlight Biosciences, Inc. | Messenger rna therapeutics and compositions |
-
2023
- 2023-08-17 CN CN202311034211.2A patent/CN116785424B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210162037A1 (en) * | 2016-05-04 | 2021-06-03 | Curevac Ag | Influenza mrna vaccines |
US20200163878A1 (en) * | 2016-10-26 | 2020-05-28 | Curevac Ag | Lipid nanoparticle mrna vaccines |
US20220370599A1 (en) * | 2021-04-30 | 2022-11-24 | Greenlight Biosciences, Inc. | Messenger rna therapeutics and compositions |
CN113372416A (zh) * | 2021-06-29 | 2021-09-10 | 山西高等创新研究院 | 流感病毒ha颈部区的突变体、重组蛋白及其应用 |
Non-Patent Citations (2)
Title |
---|
MARILÈNE BOLDUC等: "The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses", 《NANOMEDICINE》, vol. 14, no. 8, pages 2563 - 2574 * |
NCBI DATABASE: "GenBank: KX255805.1", 《GENBANK》 * |
Also Published As
Publication number | Publication date |
---|---|
CN116785424B (zh) | 2023-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7250878B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
CN108546302B (zh) | 一种复合多表位表达盒、其组成的重组病毒及应用 | |
CN101636177A (zh) | 用于禽流感的基于重组改良型痘苗病毒安卡拉(mva)的疫苗 | |
KR20120005486A (ko) | 뉴캐슬 질환 바이러스-벡터를 이용한 조류 백신 | |
CN113186173A (zh) | 一种基于减毒流感病毒载体的新型冠状病毒肺炎疫苗 | |
CN105518129B (zh) | 减毒流感疫苗和其用途 | |
WO2007068154A1 (en) | A method for preparing specific igy against mutant avian influenza virus and the preparation tηereof | |
WO2005105834A1 (es) | Procedimiento para la producción en levaduras de cápsidas virales vacías compuestas por proteínas derivadas de pvp2 del virus causante de la enfermedad de la bursitis infecciosa (ibdv) | |
CN115850396A (zh) | 一种rsv纳米颗粒疫苗及其制备方法与应用 | |
CN104611299B (zh) | 一种人工重组的h9n2禽流感病毒株、制备方法、疫苗组合物及其应用 | |
CN113862284A (zh) | 一种编码重组禽流感病毒ha蛋白的基因、病毒样颗粒、疫苗及制备与应用 | |
WO2012058493A2 (en) | Recombinant hemagglutinin protein of influenza virus and vaccine containing the same | |
CN110128545B (zh) | 一种融合基因、重组表达载体、抗原及其制备方法和应用 | |
CN116785424B (zh) | 一种mRNA多价流感疫苗及其制备方法 | |
CN106905434A (zh) | 一种包含蹄蝠肝炎病毒核心蛋白的重组融合蛋白及其制备方法和应用 | |
KR102529010B1 (ko) | 조작된 인플루엔자 헤마글루티닌 폴리펩티드의 변형 | |
CN107344969B (zh) | 一种纳米流感疫苗及构建方法和应用 | |
CN111481663B (zh) | 一种流感病毒活疫苗及其制备方法 | |
CN110229219B (zh) | 一种新型的呼吸道合胞病毒疫苗抗原的制备方法及其用途 | |
CN113827714A (zh) | 一种h7n9亚型禽流感病毒样颗粒疫苗制剂及制备和应用 | |
CN113462660A (zh) | 表达禽传染性支气管炎病毒s蛋白重组新城疫载体疫苗、制备方法及应用 | |
CN116763915B (zh) | 一种用于治疗和预防流感病毒的多价疫苗 | |
WO2023207717A1 (zh) | H5n8禽流感广谱性疫苗的开发及其应用 | |
WO2023236822A1 (zh) | H5n6禽流感广谱性疫苗的开发及其应用 | |
CN110042084A (zh) | 一种活病毒流感疫苗的生产方法以及制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |